An alternative strategy is to target the recruitment of macrophages by tumor cells through inhibiting the CCL2-CCR2 axis with CCL2-neutralizing antibodies which is currently being tested in metastatic castrate-resistant prostate cancer (NCT00992186). The gene discussed is CCR2; the disease is neoplasm.